Abbvie (ABBV) PTAB Decision Incrementally Positive, But Does Not Change Cautious Thesis - BMO

BMO Capital analyst Alex Arfaei weighed in on Abbvie (NYSE: ABBV), calling the PTAB denying institution of the Coherus (NASDAQ; CHRS) IPR of Humira formulation patent is incrementally positive for ABBV, but it does not change their cautious thesis

Arfaei commented, "We still see a long litigation path and increased uncertainty ahead. We remain cautious on Humira’s growth prospects because of increased competition from biosimilars and JAK-1s, particularly Lilly’s Baricitinib. Just as AbbVie's $3Bn Hep-C guidance by 2020 now seems unrealistic, we believe that in 2017-2018 so will the >$18Bn Humira guidance. Thus, we remain significantly below ($15Bn)."

The firm maintained a Market Perform rating and price target of $63.00

For an analyst ratings summary and ratings history on Abbvie click here. For more ratings news on Abbvie click here.

Shares of Abbvie closed at $56.04 yesterday.

You May Also Be Interested In

• AbbVie (ABBV) April weekly option implied volatility into quarter results
• Acrivon Therapeutics Inc (ACRV) PT Raised to $30 at Piper Sandler
• Symrise AG (SY1:GR) (SYIEY) PT Raised to EUR120 at CFRA